405 related articles for article (PubMed ID: 20237505)
21. DNA-binding dependent and independent functions of WT1 protein during human hematopoiesis.
Svensson E; Eriksson H; Gekas C; Olofsson T; Richter J; Gullberg U
Exp Cell Res; 2005 Aug; 308(1):211-21. PubMed ID: 15907324
[TBL] [Abstract][Full Text] [Related]
22. The WT1 Wilms' tumor suppressor gene product interacts with estrogen receptor-alpha and regulates IGF-I receptor gene transcription in breast cancer cells.
Reizner N; Maor S; Sarfstein R; Abramovitch S; Welshons WV; Curran EM; Lee AV; Werner H
J Mol Endocrinol; 2005 Aug; 35(1):135-44. PubMed ID: 16087727
[TBL] [Abstract][Full Text] [Related]
23. Wilms' tumor 1 (WT1) gene in hematopoiesis: a surrogate marker of cell proliferation as a possible mechanism of action?
Olszewski M; Huang W; Chou PM; Duerst R; Kletzel M
Cytotherapy; 2005; 7(1):57-61. PubMed ID: 16040384
[TBL] [Abstract][Full Text] [Related]
24. GATA-1 and GATA-2 binding to 3' enhancer of WT1 gene is essential for its transcription in acute leukemia and solid tumor cell lines.
Furuhata A; Murakami M; Ito H; Gao S; Yoshida K; Sobue S; Kikuchi R; Iwasaki T; Takagi A; Kojima T; Suzuki M; Abe A; Naoe T; Murate T
Leukemia; 2009 Jul; 23(7):1270-7. PubMed ID: 19212333
[TBL] [Abstract][Full Text] [Related]
25. Inhibitory mechanism of pure curcumin on Wilms' tumor 1 (WT1) gene expression through the PKCα signaling pathway in leukemic K562 cells.
Semsri S; Krig SR; Kotelawala L; Sweeney CA; Anuchapreeda S
FEBS Lett; 2011 Jul; 585(14):2235-42. PubMed ID: 21658388
[TBL] [Abstract][Full Text] [Related]
26. Wilms' tumor protein Wt1 regulates the Interleukin-10 (IL-10) gene.
Sciesielski LK; Kirschner KM; Scholz H; Persson AB
FEBS Lett; 2010 Nov; 584(22):4665-71. PubMed ID: 20974136
[TBL] [Abstract][Full Text] [Related]
27. Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation.
Cilloni D; Messa F; Gottardi E; Fava M; Arruga F; Defilippi I; Carturan S; Messa E; Morotti A; Giugliano E; Rege-Cambrin G; Alberti D; Baccarani M; Saglio G
Cancer; 2004 Sep; 101(5):979-88. PubMed ID: 15329907
[TBL] [Abstract][Full Text] [Related]
28. Role of WT1-ZNF224 interaction in the expression of apoptosis-regulating genes.
Montano G; Cesaro E; Fattore L; Vidovic K; Palladino C; Crescitelli R; Izzo P; Turco MC; Costanzo P
Hum Mol Genet; 2013 May; 22(9):1771-82. PubMed ID: 23362234
[TBL] [Abstract][Full Text] [Related]
29. Proto-oncogene N-myc promoter is down regulated by the Wilms' tumor suppressor gene WT1.
Zhang X; Xing G; Saunders GF
Anticancer Res; 1999; 19(3A):1641-8. PubMed ID: 10470095
[TBL] [Abstract][Full Text] [Related]
30. The combination of gene perturbation assay and ChIP-chip reveals functional direct target genes for IRF8 in THP-1 cells.
Kubosaki A; Lindgren G; Tagami M; Simon C; Tomaru Y; Miura H; Suzuki T; Arner E; Forrest AR; Irvine KM; Schroder K; Hasegawa Y; Kanamori-Katayama M; Rehli M; Hume DA; Kawai J; Suzuki M; Suzuki H; Hayashizaki Y
Mol Immunol; 2010 Aug; 47(14):2295-302. PubMed ID: 20573402
[TBL] [Abstract][Full Text] [Related]
31. The WT1 Wilms' tumor suppressor gene is a downstream target for insulin-like growth factor-I (IGF-I) action in PC12 cells.
Sarfstein R; Werner H
J Neurochem; 2006 Nov; 99(3):818-26. PubMed ID: 16911581
[TBL] [Abstract][Full Text] [Related]
32. The Wilms' tumor suppressor, WT1, inhibits 12-O-tetradecanoylphorbol-13-acetate activation of the multidrug resistance-1 promoter.
McCoy C; McGee SB; Cornwell MM
Cell Growth Differ; 1999 Jun; 10(6):377-86. PubMed ID: 10392899
[TBL] [Abstract][Full Text] [Related]
33. Wilms' tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation.
Loeb DM; Evron E; Patel CB; Sharma PM; Niranjan B; Buluwela L; Weitzman SA; Korz D; Sukumar S
Cancer Res; 2001 Feb; 61(3):921-5. PubMed ID: 11221883
[TBL] [Abstract][Full Text] [Related]
34. Anlaysis of complementary expression profiles following WT1 induction versus repression reveals the cholesterol/fatty acid synthetic pathways as a possible major target of WT1.
Rae FK; Martinez G; Gillinder KR; Smith A; Shooter G; Forrest AR; Grimmond SM; Little MH
Oncogene; 2004 Apr; 23(17):3067-79. PubMed ID: 15021918
[TBL] [Abstract][Full Text] [Related]
35. WT1 induces expression of insulin-like growth factor 2 in Wilms' tumor cells.
Nichols KE; Re GG; Yan YX; Garvin AJ; Haber DA
Cancer Res; 1995 Oct; 55(20):4540-3. PubMed ID: 7553624
[TBL] [Abstract][Full Text] [Related]
36. Effect of pure curcumin, demethoxycurcumin, and bisdemethoxycurcumin on WT1 gene expression in leukemic cell lines.
Anuchapreeda S; Tima S; Duangrat C; Limtrakul P
Cancer Chemother Pharmacol; 2008 Sep; 62(4):585-94. PubMed ID: 18034345
[TBL] [Abstract][Full Text] [Related]
37. Wilms' tumor protein Wt1 is an activator of the anti-Müllerian hormone receptor gene Amhr2.
Klattig J; Sierig R; Kruspe D; Besenbeck B; Englert C
Mol Cell Biol; 2007 Jun; 27(12):4355-64. PubMed ID: 17420277
[TBL] [Abstract][Full Text] [Related]
38. The role of Wilms' tumor genes.
Hirose M
J Med Invest; 1999 Aug; 46(3-4):130-40. PubMed ID: 10687307
[TBL] [Abstract][Full Text] [Related]
39. Impaired transcription factor interplay in addition to advanced glycation end products suppress podocalyxin expression in high glucose-treated human podocytes.
Drossopoulou GI; Tsotakos NE; Tsilibary EC
Am J Physiol Renal Physiol; 2009 Sep; 297(3):F594-603. PubMed ID: 19605546
[TBL] [Abstract][Full Text] [Related]
40. Poor correlation of kinetics between BCR-ABL and WT1 transcript levels after allogeneic stem cell transplantation.
Uzunel M; Ringdén O
Bone Marrow Transplant; 2004 Jan; 33(1):47-52. PubMed ID: 14704656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
